EP PerMed

European Partnership for Personalised Medicine

Overview

  • Country/ies:

    Austria , Belgium , Denmark , Estonia , Finland , France , Germany , Hungary , Iceland , Ireland , Israel , Italy , Latvia , Lithuania , Netherlands , Norway , Poland , Portugal , Romania , Spain , Sweden , Switzerland , Turkey
  • Deadline: 18-02-2025 17:00 (pre-proposals)
    17-06-2025 17:00
    (full proposal)
Home International Cooperation EP PerMed

PROGRAMME SUMMARY

The European Partnership for Personalised Medicine brings together ministries, funding organisations and research institutes from 24 countries and 10 European regions. EP PerMed builds on the results and experience of several international initiatives and projects in the field of personalised medicine, as well as more than 15 years of successful collaboration among many of the partners involved. Over the next ten years (2023-2033), most of EP PerMed’s budget will be available for funding of research projects and the implementation of personalised medicine approaches.

AIMS OF THE CALL

Topic: Pharmacogenomic Strategies for Personalised Medicine Approaches (PGxPM2025)

The overall objectives of the JTC2025 will be to

  • Support research projects in human health on pharmacogenomic strategies for personalised medicine approaches that address one or more of the following aspects:
    • identification of new pharmacogenomic markers or signatures using (multi)-omics data in relation to drug or drug combination.
    • validation of a pharmacogenomic marker or signatures using (multi)-omics data in predicting drug or drug combination outcomes.
    • use pharmaco-omics strategies to determine the right dosage, the efficacy of treatments and/or the risk of adverse drug response and non-response to treatment to tailor personalised treatment pathways, including combined treatments (multi-medication).
  • Encourage and enable interdisciplinary collaborations, i.e. multi-actor research by engaging a range of other relevant disciplines such as pre-clinical and clinical research, bioinformatics/health informatics/data research, ELSA research, implementation research or health economics research connected to the proposed research topic, including end-user perspective analysis to support the implementation of the research outcomes into clinical practice.
  • Encourage cross-sectorial collaborations, by including the private sector (e.g. SMEs, small and medium-sized enterprises), industry, as well as regulatory/HTA agencies and patient organisations.
  • Establish participatory research, i.e. active representation of patients or citizens as part of research projects.

Projects are encouraged to combine the following aspects in their research:

  1. Omics data such as epigenomics, transcriptomics, proteomics and metabolomics data in addition to genomics data in relation to treatment outcomes. A key goal is to assess the importance of one or more -omics approaches (multi-modal approaches) in optimising treatment outcomes.
  2. Information regarding patient medication (prescription and non-prescription), dose or compliance.
  3. Information (including clinical and environmental factors) regarding medication efficacy, adverse effects and patient reported outcomes (PRO).

Participatory research should be established in that active representation of patients or citizens is part of research projects. EP PerMed is supporting this approach by providing dedicated funding to organisations representing patients or citizens to participate as partners in proposals submitted to this call. Those organisations could support in designing the research, ensuring that research questions are relevant from the patients’ and citizens’ point of view. They might also support in collecting data for PROs and adverse effects.

Projects funded under this call are furthermore required to include a dedicated work package focussing on the question of implementation of the research outcomes into clinical practice with a focus on e.g. patient outcome, costs, reimbursement, education, ELSA (ethical, legal and societal aspect) or feasible use at the point of care.

Research projects in all disease areas are welcome. Research on polygenic drug response phenotypes is encouraged.

Exclusion: Projects focussing only on drug-drug-interaction are out of scope. Projects focusing on the clinical development of new drugs are out scope.

FUNDING SPECIFICS

  • The FNR supports this Call with 300,000 EUR.
  • In total, 35 funding organisations participate in this call with an available budget of over 36.5 MEUR.

APPLICATION INFORMATION

In addition to submitting at ERA PerMed, Luxembourg applicants must also submit the proposal – along with the FNR INTER documents – to the FNR via the FNR Grant Management System no later than 7 working days after the EP PerMed deadline.

Discover all INTER Calls